Why TP53 status does not associate with clinical endpoints in ovarian cancer: Facts and hypotheses
- 31 January 2006
- journal article
- editorial
- Published by Elsevier in Gynecologic Oncology
- Vol. 100 (1), 5-7
- https://doi.org/10.1016/j.ygyno.2005.08.003
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: A multivariate analysisGynecologic Oncology, 2005
- Prognostic factors in ovarian cancer: current evidence and future prospectsEuropean Journal of Cancer Supplements, 2003
- Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimenBritish Journal of Cancer, 2003
- p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancerBritish Journal of Cancer, 1999
- Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian CancerJournal of Clinical Oncology, 1999
- Chemotherapy resistance in ovarian cancer: New molecular perspectivesPublished by Wolters Kluwer Health ,1998
- p53 overexpression is Not an independent prognostic factor for patients with primary ovarian epithelial cancerCancer, 1997
- Identification of p53 genetic suppressor elements which confer resistance to cisplatinOncogene, 1997
- Cisplatin-induced apoptosis andp53 gene status in a cisplatin-resistant human ovarian carcinoma cell lineInternational Journal of Cancer, 1996
- Prognostic significance of p53 immunostaining in epithelial ovarian cancer.Journal of Clinical Oncology, 1994